APIs Cannabinoids

Benuvia manufactures GMP APIs and develops innovative chemical entities. Our cannabinoid APIs, support advanced research and therapeutic applications, meeting stringent regulatory requirements.

Cannabidiol

Cannabidiol (CBD) is a non-psychoactive phytocannabinoid derived from the Cannabis sativa plant. It is widely studied for its potential therapeutic applications, particularly in the treatment of epilepsy, anxiety, chronic pain, and inflammation. CBD interacts with the endocannabinoid system, influencing receptors such as CB1 and CB2, as well as other receptors including TRPV1 and 5-HT1A, contributing to its diverse pharmacological effects. Notably, CBD has been approved by the FDA for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in the form of Epidiolex. Additionally, CBD demonstrates anti-inflammatory, anxiolytic, and neuroprotective properties. CBD is synthetically produced and available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material. It is manufactured in compliance with Good Manufacturing Practices (GMP), making it suitable for FDA-regulated human clinical trials.

  • IUPAC Chemical Name:
    2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
  • Common Synonyms:
    (-)-trans-Cannabidiol, Delta-1(2)-trans-Cannabidiol, Resorcinol 2-p-mentha-1,8-dien-3-yl-5-pentyl-trans-(-)-
  • CAS Number: 13956-29-1
  • DEA Schedule: Not Scheduled
  • Controlled Substances Code Number (CSCN): NA

Dronabinol 

Dronabinol is the synthetic form of delta-9-tetrahydrocannabinol (Δ9-THC), the primary psychoactive component of cannabis. It is used therapeutically to alleviate nausea and vomiting associated with chemotherapy and to stimulate appetite in patients with AIDS. Dronabinol binds to CB1 receptors in the brain, affecting neurotransmitter release and modulating symptoms such as nausea and pain. It is produced in a GMP-compliant environment, ensuring its suitability for FDA-regulated clinical trials. Dronabinol is also available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material.
  • IUPAC Chemical Name:
    (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol
  • Common Synonyms:
    Marinol, Synthetic delta-9-THC
  • CAS Number: 1972-08-3
  • DEA Schedule: Schedule I
  • Controlled Substances Code Number (CSCN): 7370

Delta 8 THC

Delta-8-THC is an isomer of delta-9-THC, differing by the position of a double bond in the cannabinoid structure. It is known for producing milder psychoactive effects compared to delta-9-THC and is being investigated for potential benefits in antiemesis, anxiolysis, appetite stimulation, analgesia, and neuroprotection. Delta-8-THC binds to CB1 receptors similarly to delta-9-THC but with less potency, resulting in reduced psychoactive effects. It is produced under GMP conditions, suitable for FDA-regulated clinical trials. Delta-8-THC is synthetically produced and available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material.

  • IUPAC Chemical Name:
    (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol
  • Common Synonyms:
    Delta-8-THC, Delta-8-Tetrahydrocannabinol
  • CAS Number: 5957-75-5
  • DEA Schedule: Schedule I
  • Controlled Substances Code Number (CSCN): 7370

Cannabidivarin 

Cannabidivarin (CBDV) is a non-psychoactive cannabinoid found in the Cannabis plant, structurally similar to CBD. It has been studied for its potential in treating epilepsy and autism spectrum disorders. CBDV exhibits anticonvulsant properties and is being explored for its effects on neurodevelopmental disorders. CBDV is produced in GMP-compliant facilities, ensuring its quality for FDA-regulated human trials. It is synthetically produced and also available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material.

  • IUPAC Chemical Name:
    2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
  • Common Synonyms:
    Cannabidivarin, CBDV
  • CAS Number: 24274-48-4
  • DEA Schedule: Not Scheduled
  • Controlled Substances Code Number (CSCN): NA

Tetrahydrocannabivarin

Tetrahydrocannabivarin (THCV) is a cannabinoid found in cannabis, similar to THC but with different effects, such as appetite suppression and potential antipsychotic properties. THCV acts as a CB1 receptor antagonist at low doses and a CB1 receptor agonist at higher doses, contributing to its unique pharmacological profile. It is produced under GMP conditions, suitable for FDA-regulated clinical trials. THCV is synthetically produced and available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material.
  • IUPAC Chemical Name:
    6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol
  • Common Synonyms: THCV, Tetrahydrocannabivarin
  • CAS Number: 31262-37-0
  • DEA Schedule: Schedule I
  • Controlled Substances Code Number (CSCN): 7370

Cannabinol

Cannabinol (CBN) is a mildly psychoactive cannabinoid found in cannabis, often resulting from the oxidation of THC. It has been studied for its sedative effects and potential antibacterial properties. CBN interacts with the CB1 and CB2 receptors, albeit with less affinity compared to THC. It is produced in compliance with GMP, ensuring its suitability for FDA-regulated trials. CBN is synthetically produced and available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material.

 

  • IUPAC Chemical Name:
    6,6,9-trimethyl-3-pentyl-benzo[c]chromen-1-ol
  • Common Synonyms:
    CBN, Cannabinol
  • CAS Number: 521-35-7
  • DEA Schedule: Not Scheduled
  • Controlled Substances Code Number (CSCN): NA

Cannabigerol 

Cannabigerol (CBG) is a non-psychoactive cannabinoid found in cannabis, serving as a precursor to other cannabinoids like THC and CBD. CBG has shown potential therapeutic effects for glaucoma, inflammatory bowel disease, and bladder dysfunction. It interacts with various receptors, including CB1, CB2, and TRPV1, contributing to its pharmacological effects. CBG is produced in a GMP-compliant manner for FDA-regulated clinical trials. It is synthetically produced and available as GLP material suitable for preclinical toxicology studies or as non-GMP research grade material.

  • IUPAC Chemical Name:
    2-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-5-pentylbenzene-1,3-diol
  • Common Synonyms:
    CBG, Cannabigerol
  • CAS Number: 25654-31-3
  • DEA Schedule: Not Scheduled
  • Controlled Substances Code Number (CSCN): NA

Wish
to learn more?

Wish to learn more?

Take the next step towards unlocking your product's potential.
Let's embark on a journey of innovation and success together.

Scroll to Top